The story behind Biotech’s Biggest ever IPO.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The story behind Biotech’s Biggest ever IPO.
Released on: October 15, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Within a year of Axovant buying a shelved Phase III ready compound for Alzheimer's from GSK for $5 million, they raise $360 million as an IPO on the NYSE.
  • Summary
  • Transcript
  • Participants
  • Company
Within a year of Axovant buying a shelved Phase III ready compound for Alzheimer's from GSK for $5 million, they raise $360 million as an IPO on the NYSE. Vivek Rasaswamy, CEO of Axovant Sciences Inc., tells the story of how they achieved this to Fintan Walton, CEO of PharmaVentures.
Within a year of Axovant buying a shelved Phase III ready compound for Alzheimer's from GSK for $5 million, they raise $360 million as an IPO on the NYSE. Vivek Rasaswamy, CEO of Axovant Sciences Inc., tells the story of how they achieved this to Fintan Walton, CEO of PharmaVentures.
Vivek Ramaswamy is among the most widely respected healthcare investors, with a strong track record of biotechnology investments. Since May 2014, Mr. Ramaswamy has served as the President and Chief Executive Officer of Roivant Sciences, Inc., a drug development and commercialization services company that is wholly owned by Axovant's parent, Roivant Sciences Ltd. He also has prior experience as a successful entrepreneur in the technology industry.
Axovant Sciences Inc
Axovant Sciences is a clinical-stage biopharmaceutical company dedicated to comprehensively addressing the cognitive, behavioral, and functional components of dementia.